Antipsychotic Drugs Market (2026 - 2033)

Antipsychotic Drugs Market Summary

The global antipsychotic drugs market size was valued at USD 18.3 billion in 2025 and is projected to grow from USD 19.3 billion in 2026 to USD 29.0 billion by 2033, at a CAGR of 6.0% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 41.3% in 2025. The market is expanding due to the increasing prevalence of mental health disorders, greater awareness, and innovations.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Government support, insurance coverage, and the availability of generics are further driving accessibility, especially in emerging markets. Antipsychotic medications, also known as neuroleptics, are commonly employed to alleviate symptoms linked to psychosis. Antipsychotic medications can effectively decrease and manage various symptoms, such as paranoia and auditory hallucinations, including delusions and hearing voices. Antipsychotic medications work by inhibiting the activity of dopamine and other neurotransmitters in the brain. First and second-generation antipsychotic medications are currently available in the market.

The increasing prevalence of psychotic disorders is expected to drive the demand in the antipsychotic drugs industry. The Schizophrenia burden consistently affects men more than women, and as life expectancy improves regionally, the overall burden of Schizophrenia is expected to grow further. Aging populations also support demand, as conditions such as dementia-related psychosis become more prevalent. Market growth has been reinforced by regulatory approvals of new formulations and novel mechanisms of action, which address limitations of older therapies.

To learn more about this report, Download Free Sample Report

Advancements in technology and research in drug development have also resulted in the creation of newer and more efficient Antipsychotic drugs. Pharmaceutical companies are investing significantly in researching and developing medications with fewer side effects, higher effectiveness, and enhanced patient adherence. In September 2025, H. Lundbeck A/S and Otsuka Holdings Co., Ltd received a Complete Response Letter (CRL) from the FDA for a supplemental New Drug Application (NDA) for REXULTI (brexpiprazole) in combination with sertraline for treating adults with PTSD.

In January 2023, Eisai Co., Ltd. obtained FDA approval for Leqembi through the Accelerated Approval Pathway for Alzheimer's disease treatment. The introduction of advanced pharmaceutical choices for neurological disorders is increasing the use of antipsychotic drugs among patients worldwide.

Market Dynamics

The antipsychotic drugs market is driven by the increasing prevalence of schizophrenia, bipolar disorder, and other psychotic disorders, along with greater recognition of mental health conditions and improved access to psychiatric care. The market includes first-generation and second-generation antipsychotics, with demand gradually shifting toward atypical therapies and long-acting injectable formulations due to their potential to improve treatment adherence and reduce relapse rates. Pharmaceutical companies continue to invest in therapies with novel mechanisms of action to address unmet needs associated with symptom control and adverse effects such as metabolic disorders and extrapyramidal symptoms. The integration of digital health tools for patient monitoring and the expansion of community-based mental health services are also supporting treatment continuity. In addition, regulatory approvals for innovative therapies and ongoing clinical research focused on cognitive and negative symptoms are broadening available treatment options, supporting sustained development of the global antipsychotic drugs market.

Analyst Perspective

The antipsychotic drugs market is evolving through the development of therapies with improved efficacy, safety, and patient adherence, supported by continued advances in neuroscience research and psychiatric drug development. The market is increasingly centered on companies with established expertise in central nervous system disorders, broad clinical development programs, and global commercial capabilities. Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S continue to strengthen their positions through long-standing schizophrenia portfolios and collaborative development of innovative therapies. Janssen Pharmaceuticals, Inc. maintains a strong presence with its long-acting injectable antipsychotic portfolio, while Eli Lilly and Company has expanded treatment options through the introduction of therapies with novel mechanisms of action. Similarly, AbbVie, Inc., Teva Pharmaceutical Industries Ltd., Sumitomo Pharma Co., Ltd., Alkermes, Bristol-Myers Squibb Company, and Dr. Reddy’s Laboratories Ltd. continue to support market growth through branded products, generic medicines, lifecycle management strategies, and ongoing investment in psychiatric therapeutics.

Disease Insights

Based on disease, the schizophrenia segment led the market with the largest revenue share of 39.4% in 2025. Schizophrenia is a serious mental illness that impacts a significant number of individuals worldwide. According to the World Health Organization (WHO), Schizophrenia affects approximately 23 million people worldwide, equating to about 1 in 345 individuals. This disorder often manifests in late adolescence or early adulthood and is a leading cause of disability. Individuals with Schizophrenia typically experience a life expectancy that is 9 years shorter than the general population. The rising occurrence of Schizophrenia and related conditions and an increasing proportion of elderly individuals who are at a higher risk for developing late-onset Schizophrenia are expected to drive the segmental growth. Expanding awareness, improved diagnostic capabilities, and growing access to mental health services in emerging markets are likely to boost demand for antipsychotic therapies further.

Bipolar disorder is expected to register the fastest CAGR of 7.1% during the forecast period. The disorder significantly contributes to the global burden of disease, with affected individuals facing increased risk of suicide and substantial functional impairment. Medications and therapies for bipolar disorder are used to control symptoms of the illness. These medicines help stabilize emotions, decrease the intensity and frequency of mood changes, and enhance the overall well-being of those affected. The medications for bipolar disorder include haloperidol, olanzapine, quetiapine, and risperidone.

Drug Insights

Based on drug, the aripiprazole segment led the market with the largest revenue share of 21.0% in 2025. The adoption of third-generation products drives the sales in this segment. Furthermore, it is anticipated that product approvals are expected to experience the most significant growth during the projected period. In April 2025, Mezofy (aripiprazole) received FDA approval as an oral film formulation for treating schizophrenia in adults and patients aged 13 years and older.

The Brexpiprazole segment is expected to register the fastest CAGR during the forecast period. Brexpiprazole is a medication that alters serotonin and dopamine activity. It is used as an add-on treatment for major depressive disorder, Schizophrenia, and agitation linked to Alzheimer's disease.

Therapeutic Class Insights

Based on therapeutic class, the second generation segment led the market with the largest revenue share of 62.3% in 2025. The growth of this segment can be attributed to the presence of several second-generation medications available in the market, such as HAFYERA, INVEGA, SEROQUEL, XR, ZYPREXA, and others. Furthermore, the market's growth is expected to be propelled by the enhanced efficiency and safety of the drugs in this generation.

The third generation is expected to register the fastest CAGR during the forecast period. Increasing advancements in drug development methods are a major factor driving growth in the market. For instance, according to the study published by the National Library of Medicine in February 2024, the development of molecules that act as partial agonists and dopaminergic receptors in treating psychosis has led to the development of new and advanced drugs. This innovation has led to third-generation antipsychotics, which include medications such as aripiprazole, brexpiprazole, lurasidone, and cariprazine.

Distribution Channel Insights

Based on distribution channel, the retail pharmacies segment led the market with the largest revenue share of 42.1% in 2025. Retail pharmacies are easily available to patients and often act as the initial point of contact for individuals requiring prescription medications. Retail pharmacies carry a wide selection of antipsychotic drugs to meet the needs of individuals with different mental health disorders. They offer advice and support to patients regarding how to use medications and potential side effects, which helps increase their popularity. Many patients prefer retail pharmacies for antipsychotic medication due to their convenience, especially for long-term therapy.

To learn more about this report, Download Free Sample Report

Online pharmacies are projected to grow at the fastest CAGR over the forecast period by providing more patient convenience and easy access to medication. Online pharmacy platforms now offer features like e-prescriptions, doorstep delivery, and real-time medication tracking, ensuring timely access to essential treatments. Additionally, many online pharmacies provide 24/7 customer support and maintain strict quality control measures, including partnerships with licensed pharmacists, to ensure the authenticity and safety of medications.

Regional Insights

North America dominated the antipsychotic drugs market with the largest revenue share of 41.3% in 2025. Some of the critical factors attributable to the region’s market dominance include the strong prevalence of psychiatric illnesses in the region and the market presence of prominent biopharmaceutical companies. According to the 2024 American Psychiatric Association poll, 43% of U.S. adults reported feeling more anxious than the previous year, up from 37% in 2023. According to the National Institute of Health (NIH), approximately 57.8 million individuals in the U.S. had a mental illness in 2021. This high prevalence of mental illnesses will likely drive market growth in the region. Other contributive factors include the strong adoption of antipsychotics and technological superiority in the region.

To learn more about this report, Download Free Sample Report

U.S. Antipsychotic Drugs Market Trends

The antipsychotic drugs market in the U.S. held the largest share in the North America region in 2025 due to high rates of mental illnesses such as Schizophrenia and bipolar disorder in the country. In addition, there is significant healthcare spending, including extensive insurance coverage for mental health services. For instance, according to the article published by The White House in May 2022, the U.S. Federal Government covers some costs related to mental health disorder treatments and spent approximately USD 280 billion on mental health services in 2020. The spending on mental health services can help improve people’s access to quality mental health facilities, which is likely to drive market growth.

Europe Antipsychotic Drugs Market Trends

Europe's antipsychotic drugs industry is identified as a lucrative region. According to the WHO, more than 150 million people in Europe lived with a mental health condition in 2021, and only one in three people with depression received the care they needed. The increasing number of patients with mental disorders and the need for treatment options are key drivers of the market growth. The steady growth of the market is driven by the increasing awareness of mental health disorders, rising prevalence of conditions such as schizophrenia and bipolar disorder, and improvements in healthcare infrastructure. Moreover, digital health solutions and online pharmacy services enhance accessibility, making treatments more convenient for patients and supporting overall market growth.

Asia Pacific Antipsychotic Drugs Market Trends

The Asia Pacific antipsychotic drugs industry is expected to witness the fastest growth over the forecast period, due to a large portion of the population experiencing chronic and mental illnesses. Increasing indications, strong healthcare spending, and growing investments in healthcare infrastructure are the main factors fueling the demand for antipsychotic drugs in the region. The increasing efforts by government and private players to increase mental health awareness are further expected to drive growth in the region.

China's antipsychotic drugs market is expected to grow rapidly in the coming years due to the high prevalence of mental illnesses and efforts by authorities to create awareness and improve access to treatments. For instance, according to the WHO, approximately 41 million people in China suffer from depression. In addition, at least 80% of primary and secondary schools are expected to be equipped with mental health personnel by 2022, according to Healthy China targets. Such initiatives are expected to add growth to the market.

Latin America Antipsychotic Drugs Market & Trends

Latin America's antipsychotic drugs industry is expected to witness growth due to the systemic gaps in mental health care access and quality, and ongoing policy and clinical initiatives. However, government initiatives, such as intersectoral coordination and collaborations between emergency mental health and psychosocial support stakeholders in Brazil, are expected to help increase awareness and access to treatment in the region and drive market growth.

The antipsychotic drugs market in Argentina is likely to witness significant growth over the forecast period, owing to the rising prevalence of mental health disorders and subsequent government efforts to increase related awareness. For instance, in 2022, Argentina collaborated with the WHO for the Director General's Special Initiative for Mental Health. It is expected to help scale up mental health services, increase access, and improve coverage of about 5.2 million Argentinians by creating community-based services and strengthening secondary-level mental health services. These efforts made by the government would help people become aware of mental health, its medications, and drugs for treatment, and help the market grow over the forecast period.

MEA Antipsychotic Drugs Market & Trends

The MEA antipsychotic drugs industry is to witness significant growth in the coming years. Although it accounts for a limited market share, the current increased healthcare expenditures and awareness initiatives in this region are driving the growth in the antipsychotic market. For instance, the South African CDC launched the Mental Health Leadership Programme, which is expected to create awareness among people regarding mental health disorders.

South Africa's antipsychotic drugs market is anticipated to witness significant growth over the forecast period, due to the high prevalence of mental illnesses in the country. According to a report of Mental State of the World in 2023 report released by Sapien Labs, South Africa had the highest percentage of people with mental health disorders out of 64 countries. Various collaborations and efforts by the government to create awareness regarding mental health and treatment in the country are also expected to add to the market growth. For instance, in 2023, the South African government, for the first time, collaborated with mental health professionals to host a conference dedicated to mental health.

Key Antipsychotic Drugs Company Insights

Some of the key companies in the antipsychotic drugs market include H. Lundbeck A/S; Otsuka Pharmaceutical Co., Ltd.; Janssen Pharmaceuticals, Inc.; and Eli Lilly and Company.

• Teva Pharmaceutical Industries Ltd. is a pharmaceutical company that focuses mainly on producing generic drugs. It also has business endeavors in branded drugs, active pharmaceutical ingredients (APIs), contract manufacturing services, and an out-licensing platform. The company develops drugs for multiple medical areas, including psychiatry, oncology, and respiratory.

• Alkermes is a biopharmaceutical company that specializes in creating medications for psychiatric and neurological conditions. Alkermes has received approval for four of its own commercial drug products, which are used to treat Schizophrenia, bipolar I disorder, alcohol dependence, and opioid dependence.

Key Antipsychotic Drugs Companies

The following key companies have been profiled for this study on the antipsychotic drugs market.

• H. Lundbeck A/S

• Otsuka Pharmaceutical Co., Ltd.

• Janssen Pharmaceuticals, Inc.

• Eli Lilly and Company

• AbbVie, Inc.

• Teva Pharmaceutical Industries Ltd.

• Dr. Reddy’s Laboratories Ltd.

• Sumitomo Pharma Co., Ltd.

• Alkermes

• Bristol-Myers Squibb Company

Recent Developments

• In September 2024, Bristol Myers Squibb announced that the U.S. FDA approval of COBENFY (xanomeline and trospium chloride), a first-in-class oral medication for treating Schizophrenia in adults.

• In April 2024, Alkermes presented clinical data at the 2024 Congress of the Schizophrenia International Research Society (SIRS) from a phase 3 extension study. It aimed to assess the impact of the safety, durability, tolerability, and effectiveness of their antipsychotic drug, LYBALVI.

• In March 2024, Otsuka Pharmaceutical Co., Ltd announced that H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Europe Ltd announced the EC approval of Abilify Maintena 720mg/960mg (aripiprazole) for maintenance treatment of schizophrenia.

• In May 2024, Otsuka Pharmaceutical Co., Ltd. reported that its U.S. branch, OPDC, and Lundbeck shared results from the Phase II (Trial 061) and Phase III trials (Trial 071 and 072) on the safety and effectiveness of brexpiprazole with sertraline for treating PTSD in adults. The results were presented at the ASCP annual meeting in Miami.

• In October 2022, Lupin announced the launch of Paliperidone extended tablets, which are used in the treatment of mental disorders.

Global Antipsychotic Drugs Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global antipsychotic drugs market report based on disease, drug, therapeutic class, distribution channel, and region:

• Disease Outlook (Revenue, USD Million, 2021 - 2033)

  • Schizophrenia

  • Bipolar Disorder

  • Unipolar Depression

  • Dementia

  • Others

• Drug Outlook (Revenue, USD Million, 2021 - 2033)

  • Risperidone

  • Quetiapine

  • Olanzapine

  • Aripiprazole

  • Brexpiprazole

  • Paliperidone Palmitate

  • Others

• Therapeutic Class Outlook (Revenue, USD Million, 2021 - 2033)

  • First Generation

  • Second Generation

  • Third Generation

• Distribution Channel Class Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The Antipsychotic Drugs market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each Antipsychotic Drugs segment quantified using the revenue-capture definitions in the table below.

Estimation Model

To learn more about this report, Download Free Sample Report

The antipsychotic drugs market was estimated using an epidemiology-based patient pool model. The analysis began by identifying the country-level population and estimating the prevalence of schizophrenia, bipolar disorder, major depressive disorder requiring adjunctive antipsychotic therapy, dementia-related psychosis, and other approved indications using published epidemiological studies, government health agencies, WHO data, and mental health registries. The diagnosed patient population was derived by incorporating diagnosis rates, followed by estimation of the treated patient pool based on treatment access and prescribing practices. The treated population was further segmented by therapeutic class, individual drug molecules, and long-acting injectable formulations using prescription databases, clinical guidelines, company reports, and physician insights. Average annual treatment costs were calculated using branded and generic drug prices across major markets. Country-level revenues were aggregated to regional and global levels and validated through company revenues, prescription trends, and primary interviews with psychiatrists and industry experts.

Delivered Customizations

This report has been delivered with the following In-depth customizations